Study of overlapping setting up of Planning Target Volume for Improving Target Coverage adjacent Organ At Risk

손상위험장기에 인접한 표적 Coverage 개선을 위한 Planning Target Volume 중복 설정에 관한 연구

  • Lee, Jung Woong (Department of Radiation Oncology, Seoul National University Hospital) ;
  • Kim, Bo Kyum (Department of Radiation Oncology, Seoul National University Hospital) ;
  • Mun, Jun Ki (Department of Radiation Oncology, Seoul National University Hospital) ;
  • Woo, Hun (Department of Radiation Oncology, Seoul National University Hospital) ;
  • Lee, Yang Hoon (Department of Radiation Oncology, Seoul National University Hospital) ;
  • Jeon, Chang Woo (Department of Radiation Oncology, Seoul National University Hospital) ;
  • Lee, Jea Hee (Department of Radiation Oncology, Seoul National University Hospital)
  • 이정웅 (서울대학교병원 방사선종양학과) ;
  • 김보겸 (서울대학교병원 방사선종양학과) ;
  • 문준기 (서울대학교병원 방사선종양학과) ;
  • 우헌 (서울대학교병원 방사선종양학과) ;
  • 이양훈 (서울대학교병원 방사선종양학과) ;
  • 전창우 (서울대학교병원 방사선종양학과) ;
  • 이제희 (서울대학교병원 방사선종양학과)
  • Published : 2019.12.27

Abstract

Purpose: The purpose of this study is to improve the reduction of coverage of PTVs adjacent to organ at risk (OAR) by setting up overlapping Planning Target Volume (PTV) during Volumetric Modulated Arc Therapy(VMAT). Materials and Methods: In patients who received Whole Brain, Gall Bladder and Rectum radiation therapy, We compared the cover change, maximum dose, Homogenicity Index and Conformity Index of PTV and also compared the maximum dose and average dose change of Organ At Risk by organizing treatment plans that are not applied overlaped PTV and treatment plans that are applied overlaped PTV in areas where coverage is insufficient. Results: overage of treatment plans with overlapping PTVs was increased in all patients, and overall coverage was also increased in each of the four patients. The maximum dose for PTV was increased in five patients, and the Homogenicity Index and Conformity Index for all patients did not differ much. The maximum dose of the lens was increased by 1.12 times, and the maximum dose was decreased in two patients for brain stem. The mean dose of the eyeball was increased by a maximum of 1.15 times, and there was no significant difference between both parotid gland. In case of gallbladder cancer patients, the mean dose in the liver and colon was decreased, and the mean dose in the duodenum was increased. In the case of rectal cancer patients, the mean dose was reduced for both femur and bladder set as OARs. The overall MU was shown to be similar in four patients, excluding one. Conclusion: If the critical dose of OAR is considered and used properly, I think it is a useful way to improve coverage of PTV.

목 적: 용적변조회전 방사선치료(Volumetric Modulated Arc Therapy, VMAT)시, Planning Target Volume(PTV)을 중복 설정하여 손상위험장기(Organ At Risk, OAR)에 인접한 PTV Coverage 감소를 개선하기 위한 연구이다. 대상 및 방법: 본원에서 전뇌(Whole Brain), 담낭(Gall Bladder), 직장(Rectum) 방사선치료를 받은 환자를 대상으로 하였으며, PTV 내 Coverage가 부족한 부분에 PTV를 중복 적용한 치료계획과 적용하지 않은 치료계획으로 구성하여 Coverage 변화와 최대선량, 선량균질지수(Homogeneity Index, H.I.), 처방선량지수(Conformity Index, C.I.)를 비교하였으며, 손상위험장기(Organ At Risk, OAR)의 최대선량과 평균선량의 변화 또한 비교하였다. 결 과: 중복하여 적용한 PTV의 Coverage는 모든 환자에게서 증가하였고, 이에 따른 영향으로 전체 Coverage 또한 4명의 환자에게서 증가하였다. PTV의 최대선량은 5명의 환자에게서 증가하였으며, 모든 환자의 선량균질지수와 처방선량지수는 큰 차이를 나타내지 않았다. 수정체의 최대선량은 최대 1.12배 증가하였으나, 뇌줄기의 경우 2명의 환자에게서 최대선량이 감소하였다. 안구의 평균선량은 최대 1.15배 증가하였으며, 양측 이하선의 경우 큰 차이를 나타내지 않았다. 담낭암 환자의 경우 간과 결장의 평균선량은 각각 0.95배, 0.94배 감소하였으며, 십이지장의 평균선량은 큰 차이가 없었다. 직장암 환자의 경우 OAR로 설정한 양측 대퇴골두와 방광 모두 평균선량은 감소하였으며, 전체 MU는 1명을 제외한 4명의 환자에게서 비슷한 수준으로 나타났다. 결 론: OAR의 선량제한을 고려해가면서 적절하게 사용한다면, PTV의 Coverage 개선에 유용한 방법이라 생각한다.

Keywords

References

  1. 1M TEOH, MRCP, FRCR, 2,3C H CLARK, MSc, PhD, et al: Volumetric modulated arc therapy: a review of current literature and clinical use in practice. The British Journal of Radiology, 84 (2011), 967-996. https://doi.org/10.1259/bjr/22373346
  2. Yu CX. Intensity-modulated arc therapy with dynamic multileaf collimation: an alternative to tomotherapy. Phys Med Biol 1995;40:1435-49. https://doi.org/10.1088/0031-9155/40/9/004
  3. Yu CX, Tang G. Intensity-modulated arc therapy: principles, technologies and clinical implementation. Phys Med Biol 2011;56:R31-R54. https://doi.org/10.1088/0031-9155/56/5/R01
  4. Wang JZ, Li XA, D'Souza WD, Stewart RD. Impact of prolonged fraction delivery times on tumour contro l: a note of caution for intensity-modulated radiation therapy (IMRT). Int J Radiat Oncol Biol Phys 2003;57:543-52. https://doi.org/10.1016/S0360-3016(03)00499-1
  5. SuaYoo, Q. Jackie Wu, et al: Radiotherapy Treatment Plans With RapidArc for Prostate Cancer Involving Seminal Vesicles and Lymph Nodes. INnt J radiat Oncol Biol Phys. 2010;76:935-942. https://doi.org/10.1016/j.ijrobp.2009.07.1677
  6. Eisbruch A, Ship J, Dawson L, Kim HJ, Bradford CR, Terrell JE, Chepeha DB, Teknos TN, Hogikyan ND, Anzai Y, Marsh LH, Haken RK, Wolf GT. Salivary gland sparing and improved target irradiation by conformal and intensity modulated irradiation of head and neck cancer. World J Surg. 2003;27:832-7. https://doi.org/10.1007/s00268-003-7105-6
  7. Chung JB, Lee JW, Kim JS, Kim IA, Lee DH, et al: Comparison of target coverage and dose to organs at risk between simultaneous integrated-boost whole-field intensity-modulated radiation therapy and junctioned intensity-modulated radiation therapy with a conventional radiotherapy field in treatment of nasopharyngeal carcinoma. Radiol Phys Technol. 2011 Jul;4(2):180-4. https://doi.org/10.1007/s12194-011-0119-0
  8. T. Spalke, D. Craft, T. Bortfeld: Analyzing the main trade-offs in multiobjective radiation therapy treatment planning databases. Phys Med Biol, 54 (2009), pp. 3741-3754. https://doi.org/10.1088/0031-9155/54/12/009
  9. C. Thieke, K.H. Kufer, M. Monz, et al: A new concept for interactive radiotherapy planning with multicriteria optimization: first clinical evaluation. Radiother Oncol, 85 (2007), pp. 292-298. https://doi.org/10.1016/j.radonc.2007.06.020
  10. Cotrutz C, Lahanas M, Kappas K and Baltas D 2001 A multiobjective gradient based dose optimization algorithm for external beam conformal radiotherapy Phys. Med. Biol. 46 2161-75. https://doi.org/10.1088/0031-9155/46/8/309